Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older

NCT05096845 is registered in ClinicalTrials.gov with Livzon Pharmaceutical Group Inc. as lead sponsor.

NCT NCT05096845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05096845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older
Lead sponsor
Livzon Pharmaceutical Group Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
August 25, 2021
Completion date
June 14, 2023
Enrollment
22,500 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pandemic